Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.
Arathoon E, Bhorat A, Silaghi R, Crauwels H, Lavreys L, Tambuyzer L, Van Baelen B, Vanveggel S, Opsomer M. Arathoon E, et al. Among authors: tambuyzer l. SAGE Open Med. 2017 Jan 18;5:2050312116686482. doi: 10.1177/2050312116686482. eCollection 2017. SAGE Open Med. 2017. PMID: 28382208 Free PMC article.
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
Vingerhoets J, Calvez V, Flandre P, Marcelin AG, Ceccherini-Silberstein F, Perno CF, Mercedes Santoro M, Bateson R, Nelson M, Cozzi-Lepri A, Grarup J, Lundgren J, Incardona F, Kaiser R, Sonnerborg A, Clotet B, Paredes R, Günthard HF, Ledergerber B, Hoogstoel A, Nijs S, Tambuyzer L, Lavreys L, Opsomer M; Etravirine Cohort Study Group. Vingerhoets J, et al. Among authors: tambuyzer l. HIV Med. 2015 May;16(5):297-306. doi: 10.1111/hiv.12218. Epub 2015 Jan 14. HIV Med. 2015. PMID: 25585664 Free article. Clinical Trial.
Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients.
Orrell C, Felizarta F, Nell A, Kakuda TN, Lavreys L, Nijs S, Tambuyzer L, Van Solingen-Ristea R, Tomaka FL. Orrell C, et al. Among authors: tambuyzer l. AIDS Res Treat. 2015;2015:938628. doi: 10.1155/2015/938628. Epub 2015 Jan 15. AIDS Res Treat. 2015. PMID: 25664185 Free PMC article.
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age.
MacBrayne CE, Rutstein RM, Wiznia AA, Graham B, Alvero CG, Fairlie L, Lypen K, George KH, Townley E, Moye J Jr, Costello DG, Reding CA, Barroso Hofer C, Crauwels HM, Woot de Trixhe X, Tambuyzer L, Vanveggel S, Opsomer M, Kiser JJ; and the IMPAACT P1090 Protocol Team. MacBrayne CE, et al. Among authors: tambuyzer l. AIDS. 2021 Jul 15;35(9):1413-1421. doi: 10.1097/QAD.0000000000002902. AIDS. 2021. PMID: 33831904 Free PMC article.
Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
Tudor-Williams G, Cahn P, Chokephaibulkit K, Fourie J, Karatzios C, Dincq S, Opsomer M, Kakuda TN, Nijs S, Tambuyzer L, Tomaka FL; PIANO study group. Tudor-Williams G, et al. Among authors: tambuyzer l. HIV Med. 2014 Oct;15(9):513-24. doi: 10.1111/hiv.12141. Epub 2014 Mar 3. HIV Med. 2014. PMID: 24589294 Free article. Clinical Trial.
Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.
Vingerhoets J, Azijn H, Tambuyzer L, Dierynck I, De Meyer S, Rimsky L, Nijs S, De Smedt G, de Béthune MP, Picchio G. Vingerhoets J, et al. Among authors: tambuyzer l. AIDS Res Hum Retroviruses. 2010 Jun;26(6):621-4. doi: 10.1089/aid.2009.0239. AIDS Res Hum Retroviruses. 2010. PMID: 20507207
22 results